The mTORinhibitor rapamycin (also known as Rapamune or Sirolimus; herein referred to as“Rapa”) has been FDA approved since 1999, originally to prevent organrejection in renal transplant patients (2).Since then, Rapa or Rapa analogs (e.g., everolimus, tacrolimus, and temsirolimus)have been commonly used in the clinic for anti-rejection and cancer treatment.Numerous recent clinical trials have explored Rapa and its analogs in other clinicaluses (3, –, 8), including evaluationfor the treatment of COVID-19 (9, 10). The gene discussed is TRERF1; the disease is cancer.